JP2017529834A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017529834A5 JP2017529834A5 JP2017508487A JP2017508487A JP2017529834A5 JP 2017529834 A5 JP2017529834 A5 JP 2017529834A5 JP 2017508487 A JP2017508487 A JP 2017508487A JP 2017508487 A JP2017508487 A JP 2017508487A JP 2017529834 A5 JP2017529834 A5 JP 2017529834A5
- Authority
- JP
- Japan
- Prior art keywords
- transcription factor
- factor binding
- oligonucleotide
- oligonucleotide decoy
- binding site
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091034117 Oligonucleotide Proteins 0.000 claims description 50
- 108091023040 Transcription factor Proteins 0.000 claims description 46
- 102000040945 Transcription factor Human genes 0.000 claims description 46
- 101001139112 Homo sapiens Krueppel-like factor 9 Proteins 0.000 claims description 23
- 102100020684 Krueppel-like factor 9 Human genes 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 20
- 229940124597 therapeutic agent Drugs 0.000 claims description 20
- 208000002193 Pain Diseases 0.000 claims description 16
- 101001046599 Homo sapiens Krueppel-like factor 15 Proteins 0.000 claims description 15
- 101001139126 Homo sapiens Krueppel-like factor 6 Proteins 0.000 claims description 15
- 102100022328 Krueppel-like factor 15 Human genes 0.000 claims description 15
- 102100020679 Krueppel-like factor 6 Human genes 0.000 claims description 15
- 238000012286 ELISA Assay Methods 0.000 claims description 12
- 230000008055 nociceptive signaling Effects 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- 230000003287 optical effect Effects 0.000 claims description 6
- 101001046587 Homo sapiens Krueppel-like factor 1 Proteins 0.000 claims description 5
- 101001006895 Homo sapiens Krueppel-like factor 11 Proteins 0.000 claims description 5
- 101001006886 Homo sapiens Krueppel-like factor 12 Proteins 0.000 claims description 5
- 101001046564 Homo sapiens Krueppel-like factor 13 Proteins 0.000 claims description 5
- 101001046596 Homo sapiens Krueppel-like factor 14 Proteins 0.000 claims description 5
- 101001046589 Homo sapiens Krueppel-like factor 17 Proteins 0.000 claims description 5
- 101001139146 Homo sapiens Krueppel-like factor 2 Proteins 0.000 claims description 5
- 101001139136 Homo sapiens Krueppel-like factor 3 Proteins 0.000 claims description 5
- 101001139134 Homo sapiens Krueppel-like factor 4 Proteins 0.000 claims description 5
- 101001139130 Homo sapiens Krueppel-like factor 5 Proteins 0.000 claims description 5
- 101001139115 Homo sapiens Krueppel-like factor 8 Proteins 0.000 claims description 5
- 101000868883 Homo sapiens Transcription factor Sp6 Proteins 0.000 claims description 5
- 102100022248 Krueppel-like factor 1 Human genes 0.000 claims description 5
- 102100027797 Krueppel-like factor 11 Human genes 0.000 claims description 5
- 102100027792 Krueppel-like factor 12 Human genes 0.000 claims description 5
- 102100022254 Krueppel-like factor 13 Human genes 0.000 claims description 5
- 102100022329 Krueppel-like factor 14 Human genes 0.000 claims description 5
- 102100022249 Krueppel-like factor 17 Human genes 0.000 claims description 5
- 102100020675 Krueppel-like factor 2 Human genes 0.000 claims description 5
- 102100020678 Krueppel-like factor 3 Human genes 0.000 claims description 5
- 102100020677 Krueppel-like factor 4 Human genes 0.000 claims description 5
- 102100020680 Krueppel-like factor 5 Human genes 0.000 claims description 5
- 102100020691 Krueppel-like factor 8 Human genes 0.000 claims description 5
- 208000004296 neuralgia Diseases 0.000 claims description 5
- 208000021722 neuropathic pain Diseases 0.000 claims description 5
- 230000035897 transcription Effects 0.000 claims description 5
- 238000013518 transcription Methods 0.000 claims description 5
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 208000000094 Chronic Pain Diseases 0.000 claims description 2
- 210000003169 central nervous system Anatomy 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- -1 K LF7 Proteins 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 101001006892 Homo sapiens Krueppel-like factor 10 Proteins 0.000 description 4
- 101001046593 Homo sapiens Krueppel-like factor 16 Proteins 0.000 description 4
- 102100027798 Krueppel-like factor 10 Human genes 0.000 description 4
- 102100022324 Krueppel-like factor 16 Human genes 0.000 description 4
- 101001139117 Homo sapiens Krueppel-like factor 7 Proteins 0.000 description 1
- 102100020692 Krueppel-like factor 7 Human genes 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462037996P | 2014-08-15 | 2014-08-15 | |
| US62/037,996 | 2014-08-15 | ||
| PCT/US2015/045268 WO2016025829A1 (en) | 2014-08-15 | 2015-08-14 | Oligonucleotide decoys for the treatment of pain |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020084841A Division JP2020141688A (ja) | 2014-08-15 | 2020-05-14 | 疼痛を治療するためのオリゴヌクレオチドデコイ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017529834A JP2017529834A (ja) | 2017-10-12 |
| JP2017529834A5 true JP2017529834A5 (enExample) | 2018-09-13 |
| JP6705807B2 JP6705807B2 (ja) | 2020-06-03 |
Family
ID=55304669
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017508487A Expired - Fee Related JP6705807B2 (ja) | 2014-08-15 | 2015-08-14 | 疼痛を治療するためのオリゴヌクレオチドデコイ |
| JP2020084841A Pending JP2020141688A (ja) | 2014-08-15 | 2020-05-14 | 疼痛を治療するためのオリゴヌクレオチドデコイ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020084841A Pending JP2020141688A (ja) | 2014-08-15 | 2020-05-14 | 疼痛を治療するためのオリゴヌクレオチドデコイ |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10287583B2 (enExample) |
| EP (2) | EP3626822A1 (enExample) |
| JP (2) | JP6705807B2 (enExample) |
| CN (1) | CN106661578B (enExample) |
| AU (1) | AU2015301491A1 (enExample) |
| BR (1) | BR112017002629A2 (enExample) |
| CA (1) | CA2957250A1 (enExample) |
| ES (1) | ES2750689T3 (enExample) |
| PT (1) | PT3180434T (enExample) |
| RU (1) | RU2017108238A (enExample) |
| WO (1) | WO2016025829A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2619314T3 (es) | 2007-05-11 | 2017-06-26 | Adynxx, Inc. | Expresión génica y dolor |
| AU2013259402B2 (en) | 2012-05-10 | 2017-12-21 | Adynxx, Inc. | Formulations for the delivery of active ingredients |
| PT3180434T (pt) | 2014-08-15 | 2019-10-29 | Adynxx Inc | Chamarizes oligonucleotídicos para o tratamento da dor |
| FR3029450B1 (fr) * | 2014-12-03 | 2017-11-03 | Pole De Plasturgie De Lest | Dispositif de moulage pour la fabrication de pieces en materiau composite a partir de resine polymere liquide par injection haute pression. |
| CN113453695A (zh) * | 2018-12-24 | 2021-09-28 | 加州大学评议会 | 用嵌合体诱饵治疗脊柱病症 |
| US12031134B2 (en) | 2020-08-13 | 2024-07-09 | Nevada Research & Innovation Corporation | KLF11 siRNA for treatment of diabetes and obesity |
| EP4419684A1 (en) | 2021-10-21 | 2024-08-28 | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone | Retroelement-generated transcription factor decoys |
Family Cites Families (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6410516B1 (en) | 1986-01-09 | 2002-06-25 | President & Fellows Of Harvard College | Nuclear factors associated with transcriptional regulation |
| US5206152A (en) | 1988-04-08 | 1993-04-27 | Arch Development Corporation | Cloning and expression of early growth regulatory protein genes |
| DE3815221C2 (de) | 1988-05-04 | 1995-06-29 | Gradinger F Hermes Pharma | Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen |
| KR100225087B1 (ko) | 1990-03-23 | 1999-10-15 | 한스 발터라벤 | 피타아제의 식물내 발현 |
| US5272056A (en) | 1991-01-03 | 1993-12-21 | The Research Foundation Of State University Of New York | Modification of DNA and oligonucleotides using metal complexes of polyaza ligands |
| EP0580754A1 (en) | 1991-04-18 | 1994-02-02 | The Salk Institute For Biological Studies | Oligodeoxynucleotides and oligonucleotides useful as decoys for proteins which selectively bind to defined dna sequences |
| FR2675803B1 (fr) | 1991-04-25 | 1996-09-06 | Genset Sa | Oligonucleotides fermes, antisens et sens et leurs applications. |
| AU659482B2 (en) | 1991-06-28 | 1995-05-18 | Massachusetts Institute Of Technology | Localized oligonucleotide therapy |
| AU7518194A (en) | 1993-07-29 | 1995-02-28 | Regents Of The University Of California, The | Polynucleotide decoys that ihnibit mhc-ii expression and uses thereof |
| EP1350514A3 (en) | 1993-10-29 | 2004-07-07 | The Brigham And Women's Hospital, Inc. | Therapeutic use of cis-element decoys in vivo |
| WO1996016074A1 (en) | 1994-11-17 | 1996-05-30 | Taiho Pharmaceutical Co., Ltd. | Double-stranded oligonucleotide and carcinostatic agent containing the same as active ingredient |
| AU5369396A (en) | 1995-03-23 | 1996-10-08 | Research Foundation Of The State University Of New York, The | Rest protein and dna |
| WO1996035782A1 (en) | 1995-05-11 | 1996-11-14 | Applied Research Systems | Il-6 activity inhibitor |
| ATE357922T1 (de) | 1995-05-12 | 2007-04-15 | Anges Mg Inc | Heilung und vorbeugung von durch nf-kappab verursachten erkrankungen |
| GB9515356D0 (en) | 1995-07-26 | 1995-09-20 | Medical Res Council | Improvements in or relating to delivery of nucleic acid |
| US6265389B1 (en) | 1995-08-31 | 2001-07-24 | Alkermes Controlled Therapeutics, Inc. | Microencapsulation and sustained release of oligonucleotides |
| US6245747B1 (en) | 1996-03-12 | 2001-06-12 | The Board Of Regents Of The University Of Nebraska | Targeted site specific antisense oligodeoxynucleotide delivery method |
| DE69738454D1 (de) | 1996-05-20 | 2008-02-21 | Us Gov Health & Human Serv | Oligonukleotide welche spezifisch retrovirale nukleokapsid-proteine binden |
| US6022863A (en) | 1996-05-21 | 2000-02-08 | Yale University | Regulation of gene expression |
| EP2380906A2 (en) | 1997-06-12 | 2011-10-26 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| US6890909B1 (en) | 1997-07-04 | 2005-05-10 | Fujisawa Pharmaceutical Co., Ltd. | Brain-protective agent |
| JP3667047B2 (ja) | 1997-09-12 | 2005-07-06 | キヤノン株式会社 | 人工核酸およびその製造方法、デオキシリボフラノース化合物、リボフラノース化合物およびこれらの製造方法 |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| AU9692198A (en) | 1997-10-10 | 1999-05-03 | Kevin J. Donahue | Gene delivery compositions and methods |
| US6060310A (en) | 1997-11-24 | 2000-05-09 | The United States Of America As Represented By The Department Of Health And Human Services | Transcription factor decoy and tumor growth inhibitor |
| AU1656299A (en) | 1997-12-16 | 1999-07-05 | University Of Saskatchewan | Conductive metal-containing nucleic acids |
| AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
| JP2002516676A (ja) | 1998-06-02 | 2002-06-11 | グラクソ グループ リミテッド | 遺伝子治療法 |
| US6818626B1 (en) | 1998-07-17 | 2004-11-16 | Mirus Corporation | Chelating systems for use in the delivery of compounds to cells |
| US6423493B1 (en) | 1998-10-26 | 2002-07-23 | Board Of Regents The University Of Texas System | Combinatorial selection of oligonucleotide aptamers |
| US6008048A (en) | 1998-12-04 | 1999-12-28 | Isis Pharmaceuticals Inc. | Antisense inhibition of EGR-1 expression |
| US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US7160869B2 (en) | 1998-12-16 | 2007-01-09 | University Of Saskatchewan | Biologically active metal-containing nucleic acids |
| ATE354667T1 (de) | 1998-12-23 | 2007-03-15 | Genentech Inc | Transfectaconen, die kalciumphosphat und eine nucleinsäure enthalten |
| US6395029B1 (en) | 1999-01-19 | 2002-05-28 | The Children's Hospital Of Philadelphia | Sustained delivery of polyionic bioactive agents |
| US6333408B1 (en) | 1999-03-08 | 2001-12-25 | Kureha Chemical Industry Co., Ltd. | Oligonucleotides inhibitors of PAI-1 MRNA |
| FR2790955B1 (fr) | 1999-03-19 | 2003-01-17 | Assist Publ Hopitaux De Paris | Utilisation d'oligonucleotides stabilises comme principe actif antitumoral |
| US6387620B1 (en) | 1999-07-28 | 2002-05-14 | Gilead Sciences, Inc. | Transcription-free selex |
| CA2300328A1 (en) | 1999-09-14 | 2001-03-14 | Cardiogene Gentherap. Systeme Ag | Modulating transcription of genes in vascular cells |
| US6927027B2 (en) | 1999-12-21 | 2005-08-09 | Ingeneus Corporation | Nucleic acid multiplex formation |
| US6969704B1 (en) | 2000-08-25 | 2005-11-29 | The Trustees Of Columbia University In The City Of New York | Methods for suppressing early growth response—1protein (Egr-1) to reduce vascular injury in a subject |
| ES2335861T3 (es) | 2000-09-08 | 2010-04-06 | Universitat Zurich | Grupos de proteinas repetitivas que comprenden modulos repetitivos. |
| US6376190B1 (en) | 2000-09-22 | 2002-04-23 | Somalogic, Inc. | Modified SELEX processes without purified protein |
| DE10049549A1 (de) * | 2000-10-06 | 2002-05-02 | Markus Hecker | Modulation der Transkription pro-inflammatorischer Genprodukte |
| CA2462081A1 (en) | 2000-10-11 | 2002-04-18 | Laura Kragie | Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| EP1344536A4 (en) | 2000-11-24 | 2005-01-19 | Chugai Pharmaceutical Co Ltd | METHOD FOR REGULATING THE ACTIVITY OF EXPRESSION OF A GENETIC PRODUCT TRANSFERRED INTO A LIVING ORGANISM |
| WO2002066071A2 (en) | 2001-01-03 | 2002-08-29 | Thomas Jefferson University | Treatment of tissue fibrosis by blocking the sp1 transcription factor |
| WO2002057480A2 (en) | 2001-01-22 | 2002-07-25 | Genta Incorporated | Cell-proliferative disorder treatments using cre decoy oligomers, bcl-2 antisense and hybrid oligomers |
| WO2002066070A1 (fr) | 2001-02-20 | 2002-08-29 | Anges Mg, Inc. | Compositions pharmaceutiques contenant un leurre et procede d'utilisation associe |
| WO2002070668A2 (en) | 2001-03-06 | 2002-09-12 | Sierra Sciences, Inc. | Methods and compositions for modulating telomerase reverse transcriptase (tert) expression |
| US20030166555A1 (en) | 2001-04-02 | 2003-09-04 | Alberini Cristina M. | Methods and compositions for regulating memory consolidation |
| US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
| US20040175756A1 (en) | 2001-04-26 | 2004-09-09 | Avidia Research Institute | Methods for using combinatorial libraries of monomer domains |
| DE60236861D1 (de) | 2001-04-26 | 2010-08-12 | Amgen Mountain View Inc | Kombinatorische bibliotheken von monomerdomänen |
| EP1298141A1 (en) | 2001-09-27 | 2003-04-02 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Interleukin-4 (IL-4) promoter sequences specifically interacting with IRF-1 and IRF-2 |
| DE10148828B4 (de) | 2001-10-04 | 2005-05-19 | Avontec Gmbh | Modulation der Expression STAT-1-abhängiger Gene |
| US6663880B1 (en) | 2001-11-30 | 2003-12-16 | Advanced Cardiovascular Systems, Inc. | Permeabilizing reagents to increase drug delivery and a method of local delivery |
| CN1697647A (zh) | 2002-02-01 | 2005-11-16 | 奥默罗斯公司 | 用于抑制疼痛,炎症和软骨退化的溶液及方法 |
| US7244592B2 (en) | 2002-03-07 | 2007-07-17 | Dyax Corp. | Ligand screening and discovery |
| CN1240439C (zh) | 2002-03-28 | 2006-02-08 | 南京凯基生物科技发展有限公司 | 肿瘤基因开关药物 |
| JP4255123B2 (ja) | 2002-04-26 | 2009-04-15 | アンジェスＭｇ株式会社 | 転写ｄｎａ結合部位を含む環状ダンベルデコイオリゴデオキシヌクレオチド（ｃｄｏｄｎ） |
| DE10242319A1 (de) | 2002-09-12 | 2004-03-25 | Avontec Gmbh | Funkionelle Korrektur der-786C/T-Varianz des humanen eNOS-Gens |
| KR20150108943A (ko) | 2002-12-09 | 2015-09-30 | 아브락시스 바이오사이언스, 엘엘씨 | 약리학적 물질의 조성물 및 그 전달방법 |
| DE10257421A1 (de) | 2002-12-09 | 2004-07-08 | Grünenthal GmbH | Regulatorische Elemente im 5'-Bereich des VR1-Gens |
| WO2005004702A2 (en) | 2003-06-30 | 2005-01-20 | Massachusetts Institute Of Technology | Egr genes as targets for the diagnosis and treatment of schizophrenia |
| WO2005027830A2 (en) | 2003-09-12 | 2005-03-31 | Virginia Commonwealth University | Chimeric transcription factor decoy oligonucleotides |
| WO2005084180A2 (en) | 2003-12-19 | 2005-09-15 | University Of Cincinnati | Polyamides and polyamide complexes for delivery of oligonucleotide decoys |
| JP2005336081A (ja) | 2004-05-26 | 2005-12-08 | Anges Mg Inc | Ｎｒ２ｂ−ｎｍｄａ受容体の再発現抑制剤 |
| US7482158B2 (en) | 2004-07-01 | 2009-01-27 | Mathison Brian H | Composite polynucleic acid therapeutics |
| WO2006012625A2 (en) | 2004-07-22 | 2006-02-02 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Stat3 decoy oligonucleotides and uses therefor |
| WO2006034433A2 (en) | 2004-09-21 | 2006-03-30 | Anesiva, Inc. | Delivery of polynucleotides |
| ES2594083T3 (es) | 2004-09-28 | 2016-12-15 | Quark Pharmaceuticals, Inc. | Oligorribonucleótidos y métodos de uso de los mismos para tratamiento de la alopecia, insuficiencia renal aguda y otras enfermedades |
| CA2583576A1 (en) | 2004-10-22 | 2006-04-27 | Anges Mg, Inc. | Chimera (double) decoy |
| US7585848B2 (en) | 2005-01-11 | 2009-09-08 | Rush University Medical Center | Methods and compositions for treating, inhibiting and reversing disorders of the intervertebral disc |
| US8268572B2 (en) | 2005-03-04 | 2012-09-18 | Dana-Farber Cancer Institute, Inc. | Methods to identify inhibitors of Runx1-mediated expression of nociceptive receptors and ion channels |
| EP1877556B1 (en) | 2005-03-25 | 2011-09-14 | Medtronic, Inc. | Use of anti-tnf or anti-il1 rnai to suppress pro- inflammatory cytokine actions locally to treat pain |
| ES2845146T3 (es) | 2006-10-09 | 2021-07-26 | Neurofluidics Inc | Sistema de purificación de líquido cefalorraquídeo |
| AU2008242842B2 (en) | 2007-04-17 | 2014-06-05 | Baxter Healthcare Sa | Nucleic acid microparticles for pulmonary delivery |
| AU2014201462B2 (en) * | 2007-05-11 | 2016-09-29 | Adynxx, Inc. | Gene expression and pain |
| ES2619314T3 (es) | 2007-05-11 | 2017-06-26 | Adynxx, Inc. | Expresión génica y dolor |
| GB0906130D0 (en) * | 2008-10-03 | 2009-05-20 | Procrata Biosystems Ltd | Transcription factor decoys |
| US8609617B2 (en) * | 2009-09-04 | 2013-12-17 | University Of Miami | KLF family members regulate intrinsic axon regeneration ability |
| KR101606495B1 (ko) | 2010-08-20 | 2016-03-28 | 레플리코르 인코포레이티드 | 올리고뉴클레오타이드 킬레이트 복합체 |
| WO2012177906A1 (en) | 2011-06-21 | 2012-12-27 | Alnylam Pharmaceuticals, Inc. | Assays and methods for determining activity of a therapeutic agent in a subject |
| MX350463B (es) | 2011-07-20 | 2017-09-06 | Hospira Inc | Métodos de tratamiento del dolor. |
| AU2013259402B2 (en) * | 2012-05-10 | 2017-12-21 | Adynxx, Inc. | Formulations for the delivery of active ingredients |
| US9492506B2 (en) | 2012-05-18 | 2016-11-15 | Replicor Inc. | Oligonucleotide chelate complex—polypeptide compositions and methods |
| PT3180434T (pt) | 2014-08-15 | 2019-10-29 | Adynxx Inc | Chamarizes oligonucleotídicos para o tratamento da dor |
| WO2017151644A1 (en) | 2016-02-29 | 2017-09-08 | Adynxx, Inc. | Compositions and methods for pain amelioration via modification of gene expression |
| EP3755345A1 (en) | 2018-02-23 | 2020-12-30 | Adynxx Sub, Inc | Compositions and methods for pain amelioration in patient population that scores high on the pain catastrophizing scale |
-
2015
- 2015-08-14 PT PT158320838T patent/PT3180434T/pt unknown
- 2015-08-14 US US15/504,191 patent/US10287583B2/en not_active Expired - Fee Related
- 2015-08-14 CN CN201580042835.6A patent/CN106661578B/zh not_active Expired - Fee Related
- 2015-08-14 CA CA2957250A patent/CA2957250A1/en not_active Abandoned
- 2015-08-14 EP EP19186119.4A patent/EP3626822A1/en not_active Withdrawn
- 2015-08-14 WO PCT/US2015/045268 patent/WO2016025829A1/en not_active Ceased
- 2015-08-14 BR BR112017002629-5A patent/BR112017002629A2/pt not_active Application Discontinuation
- 2015-08-14 AU AU2015301491A patent/AU2015301491A1/en not_active Abandoned
- 2015-08-14 EP EP15832083.8A patent/EP3180434B1/en not_active Not-in-force
- 2015-08-14 ES ES15832083T patent/ES2750689T3/es active Active
- 2015-08-14 RU RU2017108238A patent/RU2017108238A/ru not_active Application Discontinuation
- 2015-08-14 JP JP2017508487A patent/JP6705807B2/ja not_active Expired - Fee Related
-
2019
- 2019-03-19 US US16/358,013 patent/US10683502B2/en not_active Expired - Fee Related
-
2020
- 2020-05-14 JP JP2020084841A patent/JP2020141688A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017529834A5 (enExample) | ||
| RU2017108238A (ru) | Олигонуклеотиды-приманки для лечения боли | |
| Boon et al. | MicroRNA-34a regulates cardiac ageing and function | |
| Shi et al. | miR-7-5p suppresses cell proliferation and induces apoptosis of breast cancer cells mainly by targeting REGγ | |
| ES2739804T3 (es) | Compuestos terapéuticos | |
| Pastori et al. | Involvement of long noncoding RNAs in diseases affecting the central nervous system | |
| Meng et al. | Towards a therapy for Angelman syndrome by targeting a long non-coding RNA | |
| Li et al. | MiR-34a inhibits proliferation and migration of breast cancer through down-regulation of Bcl-2 and SIRT1 | |
| Nóbrega et al. | Silencing mutant ataxin-3 rescues motor deficits and neuropathology in Machado-Joseph disease transgenic mice | |
| Pan et al. | MS2 VLP-based delivery of microRNA-146a inhibits autoantibody production in lupus-prone mice | |
| JP2014509512A (ja) | オリゴマーの増強された体内分布 | |
| RU2017132895A (ru) | Фармацевтическая композиция для лечения рака, содержащая микроРНК в качестве активного ингредиента | |
| Crowder et al. | Cancer stem cells under hypoxia as a chemoresistance factor in the breast and brain | |
| Yamaga et al. | RNA sequencing of MCF-7 breast cancer cells identifies novel estrogen-responsive genes with functional estrogen receptor-binding sites in the vicinity of their transcription start sites | |
| JP2013510561A5 (enExample) | ||
| MX2022015737A (es) | Compuestos para mejorar el empalme del acido ribonucleico mensajero (arnm). | |
| ES2883998T3 (es) | Inhibidores de SRSF1 para tratar trastornos neurodegenerativos | |
| Mavrikaki et al. | Overexpression of miR-9 in the nucleus accumbens increases oxycodone self-administration | |
| JP2016014070A5 (enExample) | ||
| JP2018530530A5 (enExample) | ||
| Mashanov et al. | Myc regulates programmed cell death and radial glia dedifferentiation after neural injury in an echinoderm | |
| MX2019015143A (es) | Rna guias modificados, complejos crispr-ribonucleoproteina y metodos de uso. | |
| Chen et al. | Suppression of MALAT1 ameliorates chronic constriction injury‐induced neuropathic pain in rats via modulating miR‐206 and ZEB2 | |
| JP2024102292A (ja) | Ｅｔｖ６またはｆｏｘｏ１の発現を調節する中間体ノンコーディングｒｎａ制御因子を含む組成物およびその使用 | |
| Greschik et al. | The histone code reader Spin1 controls skeletal muscle development |